Previous close | 7.95 |
Open | 7.90 |
Bid | 7.92 x 31000 |
Ask | 8.03 x 31000 |
Day's range | 7.90 - 8.00 |
52-week range | 5.14 - 9.82 |
Volume | |
Avg. volume | 148 |
Market cap | 2.959B |
Beta (5Y monthly) | 0.86 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.51 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 10 Nov 2010 |
1y target est | 35.82 |
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In this article, we will be taking a look at the 10 best healthcare stocks to buy under $20. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Best Healthcare Stocks to Buy Under $20. Global Healthcare Outlook for 2024 As 2024 progresses, the optimism surrounding the healthcare […]
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen subsidiary Norwich Pharmaceuticals' generic would infringe patents owned by Bausch's Salix Pharmaceuticals.